Medicxi Ventures Management (Jersey) Ltd

Q2 2022 13F Holdings Report, Restatement, Stock Holdings

Notable people
Kevin Stuart Johnson, Michele Ollier, Francesco de Rubertis
Signature - Title
Giles Johnstone-Scott - Director
Location
St. Helier, Jersey
Holdings as of
30 Jun 2022
Value $
$240,803,000
Num holdings
6
Filing time
03 Aug 2022, 11:09:57 UTC
Form type
13F-HR/A-1 - Restatement
Description
All US holdings of this investor are reported in this report. Top holdings included CNTA, AURA, PCVX, MRUS, and PHAT.
Previous filing
Q1 2022 - 12 May 2022
Next filing
Q3 2022 - 25 Oct 2022
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2022 Q2 - Restatement compared to 2022 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Giles Johnstone-Scott Director St. Helier, Jersey 03 Aug 2022

Amendment being filed to include the number of Phathom Pharmaceuticals shares under Column 8 for the number of voting securities and is the only basis for being a "restatement".

Other Included Managers (1):

Num Name Location File Number
1 Francesco De Rubertis